NLRP3 and coronary artery disorder: As far as plaque vulnerability is concerned, NLRP3 inflammasome expression was shown to be higher in patients with an ACS, followed by patients with stable angina, compared to those without coronary artery disease [34,35,36], showing a link between plaque vulnerability and clinical outcomes.